EGFR and non-small cell lung carcinoma: Consequently, the phase III FLAURA-2 (n = 557), assessing first-line osimertinib +/− CT, and MARIPOSA (n = 1074), assessing the combination of amivantamab and lazertinib vs. osimertinib monotherapy, further refined first-line strategies for EGFR-mutant NSCLC.